ERBB2 and triple-negative breast carcinoma: Across all cases, triple-negative breast cancer (TNBC) was the most prevalent subtype (42.8%), followed by ER/PR-positive tumors (36.9%), HER2-positive disease (16.8%), and TPBC (3.5%) (Supplementary Table 8).